Aditxt Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aditxt.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Aditxt gains on regaining compliance with Nasdaq listing requirements

Sep 29

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Sep 13

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Jul 08

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aditxt has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:ADTX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	0	-47	-14	-14	N/A
6/30/2024	0	-43	-20	-20	N/A
3/31/2024	1	-41	-21	-21	N/A
12/31/2023	1	-33	-19	-19	N/A
9/30/2023	1	-30	-22	-22	N/A
6/30/2023	1	-27	-22	-22	N/A
3/31/2023	1	-28	-21	-21	N/A
12/31/2022	1	-28	-23	-22	N/A
9/30/2022	1	-43	-25	-24	N/A
6/30/2022	1	-46	-22	-21	N/A
3/31/2022	0	-46	-24	-23	N/A
12/31/2021	0	-46	-23	-22	N/A
9/30/2021	N/A	-27	-18	-17	N/A
6/30/2021	N/A	-20	-17	-16	N/A
3/31/2021	N/A	-14	-12	-11	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-5	-4	-4	N/A
6/30/2020	N/A	-4	-1	-1	N/A
3/31/2020	N/A	-6	0	0	N/A
12/31/2019	N/A	-6	0	0	N/A
9/30/2019	N/A	-5	0	0	N/A
6/30/2019	N/A	-6	-1	-1	N/A
3/31/2019	N/A	-5	-1	-1	N/A
12/31/2018	N/A	-6	0	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ADTX's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if ADTX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ADTX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ADTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ADTX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ADTX's Return on Equity is forecast to be high in 3 years time

Aditxt Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors

Aditxt Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirements

Aditxt, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. has filed a Follow-on Equity Offering in the amount of $1.197058 million.

Aditxt, Inc. announced that it has received $0.5 million in funding

Aditxt, Inc., Annual General Meeting, Aug 07, 2024

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced that it expects to receive $4.2 million in funding

Aditxt, Inc. announced delayed annual 10-K filing

Aditxt, Inc. announced that it has received $6.000003 million in funding

Aditxt Regains Compliance with Nasdaq Stockholders' Equity Requirement

Aditxt, Inc. (NasdaqCM:ADTX) entered into an agreement and plan of merger to acquire Evofem Biosciences, Inc. (OTCPK:EVFM) from shareholders.

Third quarter 2023 earnings released: US$47.13 loss per share (vs US$211 loss in 3Q 2022)

Aditxt, Inc. Announces Board Changes

Nasdaq Hearings Panel Grants Aditxt an Exception through December 26, 2023 to Allow Aditxt to Complete its Plan to Demonstrate Compliance with the Equity Rule

Aditxt Receives Written Notice from Nasdaq

Aditxt, Inc. announced that it has received $10 million in funding

Aditxt, Inc. announced that it expects to receive $10 million in funding

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$6.42 loss in 2Q 2022)

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt Receives Notice from Nasdaq Due to Non-Compliance with Minimum Stockholders Equity Requirement

Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection

Aditxt Regains Compliance with Nasdaq Listing Requirements

Aditxt gains on regaining compliance with Nasdaq listing requirements

Aditxt, Inc. has completed a Follow-on Equity Offering.

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

Aditxt Provides Update on AditxtReprogramming’s Apoptotic DNA Immunotherapy Therapeutic Platform

High number of new directors

Aditx Therapeutics, Inc. Announces Enhancements to Its Aditxtscore for COVID-19

Aditxt adds Lauren Chung to board of directors

Co-Founder exercised options to buy US$60k worth of stock.

Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services

New 90-day high: US$4.10

ADiTx Therapeutics, Inc. Appoints Dolly B. Tyan as Senior Vice President of Clinical Development - Transplantation

Aditx Therapeutics, Inc. Announces the Operational Launch of the AditxtScore™ Immune Monitoring Platform

New 90-day high: US$2.61

Aditxt Signs Distribution Agreement with Todos Medical Ltd. for Aditxtscore™ for Covid-19 Immune Monitoring Service

Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring

New 90-day high: US$2.39

We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Aditx Therapeutics, Inc. Appoints Anthony Voorhies as Head of Business Development for AditxtScore

Aditx Therapeutics, Inc. Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test

ADiTx Therapeutics, Inc. has completed a Composite Units Offering in the amount of $9.6 million.

ADiTx Therapeutics, Inc. has completed an IPO in the amount of $11.040012 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies